Estudo randomizado | Nivolumabe neoadjuvante com quimioterapia no câncer ressecável de pulmão.
14 Abr, 2022 | 16:46hNeoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer – New England Journal of Medicine
Comunicado de imprensa: Immunotherapy Plus Chemotherapy Before Surgery Improves Outcomes for Patients with Lung Cancer – Johns Hopkins Medicine
Comentário no Twitter
In patients with resectable NSCLC, neoadjuvant nivolumab plus chemo results in longer event-free survival and a greater likelihood of pathological complete response than chemo alone. #AACR22 https://t.co/ILjdRZQ7dJ pic.twitter.com/1JfiUw18R6
— NEJM (@NEJM) April 11, 2022